We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current TARS market cap is 1.26B. The company's latest EPS is USD -3.9713 and P/E is -9.28.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 10M | 2.5M | 0 | 1.87M |
Operating Income | -22.91M | -15.06M | -24.95M | -32.82M | -40.94M |
Net Income | -22.51M | -13.6M | -23.42M | -31.42M | -39.15M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 57.03M | 25.82M | 17.45M |
Operating Income | -4.3M | -27M | -12.16M | -62.71M | -143.16M |
Net Income | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 236.47M | 227.86M | 211.21M | 188.93M | 268.33M |
Total Liabilities | 33.84M | 34.96M | 37.81M | 41.2M | 54.67M |
Total Equity | 202.63M | 192.9M | 173.4M | 147.73M | 213.66M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 58.32M | 171.97M | 178.91M | 227.86M | 265.49M |
Total Liabilities | 919k | 5.99M | 12.18M | 34.96M | 68.5M |
Total Equity | -6.01M | 165.98M | 166.73M | 192.9M | 196.99M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -38.16M | -49.03M | -21.97M | -45.8M | -78.16M |
Investing | -57.41M | -144.63M | 11.29M | 75.39M | 122.75M |
Financing | 93.72M | 93.99M | 5.01M | 5.52M | 110.42M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M |
Investing | -175k | -456k | -586k | -144.63M | 140.6M |
Financing | 59.45M | 131.77M | 21k | 93.99M | 130.18M |
Market Cap | 1.26B |
Price to Earnings Ratio | -9.28 |
Price to Sales Ratio | 72.27 |
Price to Cash Ratio | 5.61 |
Price to Book Ratio | 6.4 |
Dividend Yield | - |
Shares Outstanding | 34.22M |
Average Volume (1 week) | 607.88k |
Average Volume (1 Month) | 503.99k |
52 Week Change | 140.07% |
52 Week High | 40.40 |
52 Week Low | 12.57 |
Spread (Intraday) | 23.95 (40.63%) |
Company Name | Tarsus Pharmaceuticals Inc |
Address |
3500 s dupont hwy dover, delaware 19901 |
Website | https://www.tarsusrx.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions